Eritrodermia psoriática en un hombre joven: sospechar infección por VIH

Arellano, Javier; Yagnam, Mathias; Vidal, Martín; Corredoira, Yamile

doi:10.4067/s0716-10182017000600603

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[22] Erythrodermic psoriasis is considered an acute condition in which >90% of the body is covered with inflamed surfaces and is considered a skin marker of HIV infection when occurs in recalcitrant psoriasis or in previously healthy patients. [23,24] Archives of Pharmacy Practice ¦ Volume 12 ¦ Issue 1 ¦ January-March 20211…”

Section: Reviewmentioning

confidence: 99%

A review on updates in management and Treatment of Psoriasis

Alhammad¹,

Aseri²,

Alqahtani³

et al. 2021

Arch Pharma Pract

View full text Add to dashboard Cite

Introduction: Introduction: Psoriasis is a rather common inflammatory skin disease that is characterized by the appearance of red scaly plaques and may affect any part of the body. There are certain factors that make psoriasis a challenge for physicians, these include: high prevalence, disability, chronicity, disfiguration, and associated comorbidities. The approach to the management of Psoriatic patients should also take into account the dermatological clinical features. This review would discuss and focus on recent updates in the management of Psoriatic patients and its common related issues as well as the clinical picture of psoriasis in order to understand and inform medical practitioners and develop their knowledge of the etiology of the condition, immune and environmental factors, has led to the development of precision-targeted therapies that alleviate patient morbidity. Methodology: PubMed database was searched and screened for relevant observational studies, systematic reviews, randomized controlled trials, meta-journal articles, and journal articles containing the term used in the mesh "Psoriasis", "Management" "Treatment trials" within the title or abstract. Conclusion: The physician should adhere to updated evidence-based guidelines in the management of psoriatic patients. New biologic modalities and alternative nature-based treatments for psoriasis should be studied. Pharmacodynamics profiles, administration modality, and dosing regimens for the currently available IL-17 and IL-23 inhibitors must be reexamined to improve the overall continuity of care of psoriasis patients.

show abstract

Section: Reviewmentioning

confidence: 99%